Renova Therapeutics expands clinical development team with latest hire

SAN DIEGO, June 1, 2016 /PRNewswire-USNewswire/ -- Renova™ Therapeutics, a biopharmaceutical company developing gene therapy treatments for congestive heart failure and other chronic diseases, has hired Michele Martorana, BSN, RN, as Clinical Research Manager.

Ms. Martorana, a registered nurse, joins Renova Therapeutics after working as a clinical research consultant for the company. In her new role, Ms. Martorana will coordinate the conduct of the company's clinical trials with multiple contract research organizations. She will report to the Executive Vice President of Clinical Development.

Her responsibilities will include assisting the Executive Vice President of Clinical Development in protocol preparation, developing case report forms with vendors, and initiating investigative sites in all geographic areas. She will also be responsible for the periodic and final review of the accuracy and integrity of data from individual clinical trial sites and in aggregate. Ms. Martorana will serve as the primary Renova Therapeutics contact for clinical questions from investigators on patient eligibility and enrollment using protocol-specific inclusion and exclusion criteria. She will support the company's regulatory filings, monitor site-specific study coordinators' performance, and verify site performance for rates of enrollment, protocol violations and quality of case report forms completion.

"Michele will be vital to our work in advancing further clinical trials, especially RT-100 for heart failure," said Dr. Richard McCloskey, Executive Vice President of Clinical Development, Renova Therapeutics. "As we gear up for pivotal trials with this promising gene therapy candidate, she will be critical in providing hands-on support to ensure well-managed execution of this important next step for the company."

Prior to supporting Renova Therapeutics, Ms. Martorana was a nurse at the VA Health Administration in Biloxi, Ms. She is a licensed registered nurse in California and Mississippi and holds a Bachelor of Science in Nursing from the University of Southern Mississippi School of Nursing.

"I look forward to working alongside Dr. McCloskey and the Renova [Therapeutics] team to move the gene therapy pipeline forward," said Ms. Martorana. "As a nurse, I've seen the incredible impact that innovative medicines have on patients' lives. It's great to be working toward getting Renova's gene therapies to the people who need them the most."

About Renova Therapeutics 
Renova™ Therapeutics is developing definitive, one-time gene therapy treatments to restore the health of people suffering from chronic diseases. The first two indications the company is pursuing are therapies for congestive heart failure (CHF) and type 2 diabetes, two of the most common and devastating chronic diseases in the world. The company's lead product, RT-100, is a treatment that delivers a therapeutic gene directly to the heart during a routine outpatient procedure and has the potential to increase heart function in millions of patients with CHF. The company's product pipeline also includes a second-generation therapy for CHF patients and a groundbreaking therapy in preclinical stage for sufferers of type 2 diabetes. Renova Therapeutics was founded in 2009 and is led by an experienced management team in biopharmaceuticals and gene therapy. For additional information about the company, please visit www.renovatherapeutics.com.

Photo - http://photos.prnewswire.com/prnh/20160531/373944
Logo - http://photos.prnewswire.com/prnh/20151231/318660LOGO

SOURCE Renova Therapeutics

Related Links

http://www.renovatherapeutics.com